[go: up one dir, main page]

MA31702B1 - Derive de 4-pyrimidinesulfamide - Google Patents

Derive de 4-pyrimidinesulfamide

Info

Publication number
MA31702B1
MA31702B1 MA32692A MA32692A MA31702B1 MA 31702 B1 MA31702 B1 MA 31702B1 MA 32692 A MA32692 A MA 32692A MA 32692 A MA32692 A MA 32692A MA 31702 B1 MA31702 B1 MA 31702B1
Authority
MA
Morocco
Prior art keywords
compound
pyrimidinesulfamide
derivative
pyrimidinesulfamide derivative
salts
Prior art date
Application number
MA32692A
Other languages
Arabic (ar)
English (en)
Inventor
Martin Bolli
Christoph Boss
Alexander Treiber
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40140023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31702(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA31702B1 publication Critical patent/MA31702B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

L'invention porte sur le composé représenté par la formule structurale (i) et sur les sels de celui-ci. Ledit composé est utile en tant qu'antagoniste du récepteur de l'endothéline. L'invention porte en outre sur un procédé pour préparer ledit composé.
MA32692A 2007-08-17 2010-03-12 Derive de 4-pyrimidinesulfamide MA31702B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2007053292 2007-08-17
IB2008052571 2008-06-26
PCT/IB2008/053282 WO2009024906A1 (fr) 2007-08-17 2008-08-15 Dérivé de 4-pyrimidinesulfamide

Publications (1)

Publication Number Publication Date
MA31702B1 true MA31702B1 (fr) 2010-09-01

Family

ID=40140023

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32692A MA31702B1 (fr) 2007-08-17 2010-03-12 Derive de 4-pyrimidinesulfamide

Country Status (31)

Country Link
US (1) US8324232B2 (fr)
EP (1) EP2190837B1 (fr)
JP (1) JP5323075B2 (fr)
KR (1) KR101528946B1 (fr)
CN (1) CN101772494B (fr)
AR (1) AR070018A1 (fr)
AU (1) AU2008290234B2 (fr)
BR (1) BRPI0815360B8 (fr)
CA (1) CA2695511C (fr)
CY (1) CY1113255T1 (fr)
DK (1) DK2190837T3 (fr)
ES (1) ES2394584T3 (fr)
FI (1) FIC20240041I1 (fr)
FR (1) FR24C1047I1 (fr)
HK (1) HK1144196A1 (fr)
HR (1) HRP20120878T1 (fr)
HU (1) HUS2400041I1 (fr)
IL (1) IL203936A (fr)
MA (1) MA31702B1 (fr)
MX (1) MX2010001837A (fr)
MY (1) MY152281A (fr)
NL (1) NL301304I2 (fr)
NO (1) NO2024053I1 (fr)
NZ (1) NZ583990A (fr)
PL (1) PL2190837T3 (fr)
PT (1) PT2190837E (fr)
RU (1) RU2485116C2 (fr)
SI (1) SI2190837T1 (fr)
TW (1) TWI411437B (fr)
WO (1) WO2009024906A1 (fr)
ZA (1) ZA201001872B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2907811A1 (fr) * 2014-02-14 2015-08-19 Actelion Pharmaceuticals Ltd. Procédé de fabrication de dérivés de sulfamide de pyrimidine
WO2017093903A1 (fr) * 2015-11-30 2017-06-08 Laurus Labs Private Limited Procédé amélioré de préparation de macitentane
WO2017191565A1 (fr) * 2016-05-04 2017-11-09 Shilpa Medicare Limited Procédé de préparation de macitentan
EP3658140A1 (fr) * 2017-02-27 2020-06-03 Idorsia Pharmaceuticals Ltd Combinaisons d'un dérivé de 4-pyrimidinesulfamide avec des principes actifs pour le traitement de maladies liées à l'endothéline
US12144811B2 (en) * 2017-11-30 2024-11-19 Idorsia Pharmaceuticals Ltd Combination of a 4-pyrimidinesulfamide derivative with an SGLT-2 inhibitor for the treatment of endothelin related diseases
CN108997223B (zh) * 2018-08-09 2020-06-30 浙江先锋科技股份有限公司 5-(4-溴苯基)-4，6-二氯嘧啶的制备方法
TWI841649B (zh) 2018-12-21 2024-05-11 瑞士商艾克泰聯製藥有限公司 用於治療肺動脈高血壓之醫藥組成物
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
EP4056182A1 (fr) * 2019-11-07 2022-09-14 Crystal Pharmaceutical (Suzhou) Co., Ltd. Forme cristalline d'aprocitentan, son procédé de préparation et son utilisation
US20230167090A1 (en) 2020-05-21 2023-06-01 Teva Pharmaceuticals International Gmbh Solid state forms of aprocitentan and process for preparation thereof
WO2023111797A1 (fr) * 2021-12-17 2023-06-22 Janssen Biotech, Inc. Dérivés de pyrimidinsulfamides et procédé de fabrication associé
CN119255805A (zh) 2022-05-22 2025-01-03 爱杜西亚药品有限公司 用于治疗高血压的阿普昔腾坦
KR20250019676A (ko) 2022-05-25 2025-02-10 이도르시아 파마슈티컬스 리미티드 소듐 (5-(4-브로모페닐)-6-(2-((5-브로모피리미딘-2-일)옥시)에톡시)피리미딘-4-일)(술파모일)아미드의 결정질 형태

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2801584A1 (de) 1978-01-14 1979-07-19 Bayer Ag Halogensubstituierte pyrimidin (2)yl-thiono-thiol-phosphor(phosphon)- saeureester, verfahren zu ihrer herstellung und ihre verwendung als insektizide und akarizide
JPH04103525A (ja) 1990-08-22 1992-04-06 Sanwa Kagaku Kenkyusho Co Ltd 難水溶性薬物の持続性製剤化方法
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW394761B (en) 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
US5523204A (en) 1993-12-10 1996-06-04 Becton Dickinson And Company Detection of nucleic acids in cells by strand displacement amplification
WO1996016963A1 (fr) 1994-11-25 1996-06-06 F. Hoffmann-La Roche Ag Sulfonamides et leur utilisation comme medicaments
TW313568B (fr) 1994-12-20 1997-08-21 Hoffmann La Roche
US5739333A (en) 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
TW442301B (en) 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
WO1997022595A1 (fr) 1995-12-20 1997-06-26 Yamanouchi Pharmaceutical Co., Ltd. Derives arylethenesulfonamide et composition de medicaments renfermant ces derives
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
TWI284642B (en) 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides
HUP0201402A3 (en) 1999-09-03 2003-12-29 Actelion Pharmaceuticals Ltd Bis-sulfonamides, process for their preparation and pharmaceutical compositions containing them
AU3536701A (en) 1999-12-22 2001-07-03 Actelion Pharmaceuticals Ltd Butyne diol derivatives
US20040062803A1 (en) 1999-12-22 2004-04-01 Hedden David B. Sustained-release formulation of a cyclooxygenase-2 inhibitor
EP1244657B1 (fr) 1999-12-31 2004-12-29 Encysive Pharmaceuticals Inc. Sulfonamides et leurs derives modulant l'activite de l'endotheline
WO2001081335A1 (fr) 2000-04-20 2001-11-01 Actelion Pharmaceuticals Ltd Pyrimidine-sulfonamides agissant comme antagonistes de l'endotheline
AU2001265871A1 (en) 2000-04-25 2001-11-07 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
JP2001335469A (ja) 2000-05-26 2001-12-04 Lion Corp 固体製剤の製造方法
MXPA02012795A (es) 2000-06-28 2004-07-30 Teva Pharma Carvedilol.
WO2002046172A2 (fr) 2000-12-07 2002-06-13 Cv Therapeutics, Inc. Composes d'augmentation d'abca-1
WO2002053557A1 (fr) 2000-12-18 2002-07-11 Actelion Pharmaceuticals Ltd Nouveaux sulfamides et leur utilisation comme antagonistes du recepteur de l'endotheline
FR2819720B1 (fr) 2001-01-22 2004-03-12 Fournier Lab Sa Nouveaux comprimes de fenofibrate
KR20030041577A (ko) 2001-11-20 2003-05-27 디디에스텍주식회사 난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물
EP1480679B1 (fr) 2002-02-26 2007-05-23 Astrazeneca AB Formulation pharmaceutique d'iressa comprenant un derive de cellulose soluble dans l'eau
US7452896B2 (en) * 2002-12-02 2008-11-18 Actelion Pharmaceuticals Ltd. Pyrimidine-sulfamides and their use as endothelian receptor antagonist
AU2004216258B2 (en) 2003-02-25 2006-10-19 Eli Lilly And Company Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride
MY151003A (en) * 2005-09-12 2014-03-31 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
AU2009215329B2 (en) 2008-02-20 2014-08-21 Actelion Pharmaceuticals Ltd Combination comprising paclitaxel for treating ovarian cancer
PT2315587T (pt) 2008-08-13 2018-01-31 Actelion Pharmaceuticals Ltd Produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan

Also Published As

Publication number Publication date
BRPI0815360A8 (pt) 2017-12-26
KR20100052517A (ko) 2010-05-19
JP2010536742A (ja) 2010-12-02
NZ583990A (en) 2012-06-29
AU2008290234A1 (en) 2009-02-26
CA2695511C (fr) 2015-11-03
DK2190837T3 (da) 2012-10-08
HK1144196A1 (en) 2011-02-02
FIC20240041I1 (fi) 2024-12-02
NO2024053I1 (no) 2024-12-03
CN101772494A (zh) 2010-07-07
PT2190837E (pt) 2012-10-31
BRPI0815360B1 (pt) 2018-12-04
CA2695511A1 (fr) 2009-02-26
TW200927122A (en) 2009-07-01
TWI411437B (zh) 2013-10-11
KR101528946B1 (ko) 2015-06-15
AU2008290234B2 (en) 2013-11-21
WO2009024906A1 (fr) 2009-02-26
IL203936A (en) 2016-03-31
ZA201001872B (en) 2011-05-25
HUS2400041I1 (hu) 2024-12-28
RU2485116C2 (ru) 2013-06-20
MX2010001837A (es) 2010-03-10
ES2394584T3 (es) 2013-02-04
JP5323075B2 (ja) 2013-10-23
CY1113255T1 (el) 2016-04-13
RU2010109543A (ru) 2011-09-27
HRP20120878T1 (hr) 2012-11-30
BRPI0815360B8 (pt) 2021-05-25
NL301304I2 (nl) 2024-12-19
EP2190837B1 (fr) 2012-08-15
BRPI0815360A2 (pt) 2015-02-10
PL2190837T3 (pl) 2013-01-31
AR070018A1 (es) 2010-03-10
SI2190837T1 (sl) 2012-11-30
FR24C1047I1 (fr) 2025-01-10
EP2190837A1 (fr) 2010-06-02
US8324232B2 (en) 2012-12-04
CN101772494B (zh) 2013-05-15
MY152281A (en) 2014-09-15
US20120142716A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
MA31702B1 (fr) Derive de 4-pyrimidinesulfamide
NO20084783L (no) Syntese av acylaminoalkenylenamider nyttige som substans P antagonister
HRP20120129T8 (en) Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
CY1113084T1 (el) ΠΑΡΑΓΩΓΟ ΒΕΝΖΙΜΙΔΑΖΟΛΗΣ ΚΑΙ Η ΧΡΗΣΗ ΑΥΤΟΥ ΩΣ ΑΝΤΑΓΩΝΙΣΤΟΥ ΤΟΥ ΥΠΟΔΟΧΕΑ aii
MA33240B1 (fr) Inhibiteurs de bêta-sécrétase
EA200901039A1 (ru) Способ получения производного бензимидазола
EA200800886A1 (ru) Способ получения 1-н-имидазо[4,5-с]пиридинов и их аналогов
CL2008002169A1 (es) Metodo para preparar un compuesto derivado de tetrahidro-2h-piran-3,4,5-triol-2,6-disustituido, inhibidor del contransportador de sodio y glucosa 2; compuestos intermediarios; y metodo de preparacion de los compuestos intermediarios.
EP2200606A4 (fr) Procédé pour la préparation de composés utiles en tant qu'inhibiteurs de sglt
MY148434A (en) Fused bicyclic heteroaryl derivatives
ES2640911T3 (es) Cicloalquilnitrilpirazolcarboxamidas como inhibidores de la quinasa Janus
WO2009154754A3 (fr) Synthèse de dérivés de morpholine deutérés
EA200970604A1 (ru) Новое промежуточное соединение и способ, используемый для получения {2-[1-(3,5-бис-трифторметилбензил)-5-пиридин-4-ил-1н-[1,2,3]триазол-4-ил]пиридин-3-ил}-(2-хлорфенил)метанона
NZ587518A (en) Crystalline form III of (3,5-bis trifluoromethyl)-N-[4-methyl-3-({ 4-(pyridin-3 yl)-pyrimidin-2-yl} amino)-phenyl]-benzamide
MX2009003257A (es) Procedimiento para la sintesis de derivados de fenoxi diaminopirimidina.
NO20071112L (no) Nye heterosykliske karboksylsyreamidderivater
MX2012004644A (es) Compuestos de indazol y pirazolopiridina como antagonistas del receptor de ccr1.
MX2017017022A (es) Metodo para la sintesis de derivados de rapamicina.
RU2013137753A (ru) Твердые формы ингибитора гиразы (r)-1-этил-3-[5-[2-(1-гидрокси-1-метилэтил)пиримидин-5-ил]-7-(тетрагидрофуран-2-ил)-1н-бензимидазол-2-ил]мочевины
MY158747A (en) Glucocorticoid receptor agonist comprising 2, 2, 4- trimethyl-6-phenyl-1,2-dihydroquinoline derivatives having substituted oxy group
CY1117087T1 (el) Διαδικασια για την παρασκευη εστερων (5-φθορο-2-μεθυλο-3-κινολιν-2-υλμεθυλ-ινδoλ-1-υλ)- οξικου οξεος
AR048875A1 (es) Un proceso para preparar montelukast y compuestos intermedios para el mismo
MX2010009876A (es) Nuevo proceso para la preparacion de derivados de acido ciclohexanocarboxilico por medio del derivado de ciclohexanocarboxamida correspondiente.
TN2011000620A1 (en) Novel fumarate salts of a histamine h3 receptor antagonist
AR045548A1 (es) Derivados de imidazol